Peyronie’s disease is a complex, often underdiagnosed urological condition that can have a significant impact on a man’s quality of life, both functionally and psychologically. It is characterized by the formation of fibrous plaques within the tunica albuginea of the penis, the structure that surrounds the corpora cavernosa and contributes to the mechanism of erection. These areas of fibrosis cause a loss of tissue elasticity, resulting in penile curvature during erection, sometimes associated with pain and difficulty during sexual intercourse.
The cause of the condition is not fully understood, but it is generally attributed to repeated microtrauma to the penis—often unrecognized by the patient—which triggers an abnormal inflammatory response in susceptible individuals. This process leads to excessive collagen deposition and the formation of fibrotic plaque. Genetic factors, systemic conditions such as diabetes or connective tissue diseases, and habits such as smoking can contribute to the development and progression of the disease.
From a clinical perspective, Peyronie’s disease typically progresses through an initial phase, known as the inflammatory or active phase, and a subsequent stable phase. During the active phase, the patient may experience pain during erection and notice a gradual onset or worsening of the curvature. In the stable phase, however, the pain tends to decrease or disappear, while the penile deformity stabilizes. It is precisely during the initial phase that timely treatment can help limit the progression of the condition.
In recent years, among conservative treatment options, intralesional hyaluronic acid injections have garnered growing interest due to their safety profile and potential clinical benefits. Hyaluronic acid is a molecule naturally present in the body’s tissues, with moisturizing, anti-inflammatory, and tissue-repair-modulating properties. Its administration directly at the site of the fibrotic plaque aims to reduce local inflammation and improve tissue elasticity.
Several clinical studies have shown that hyaluronic acid injections can help reduce penile curvature, improve erectile quality, and alleviate pain, especially when treatment is initiated in the early stages of the condition. The mechanism of action appears to be linked not only to hyaluronic acid’s ability to modulate the inflammatory response, but also to its influence on collagen remodeling processes.
The treatment is generally performed on an outpatient basis and involves a series of injections administered at intervals, following protocols that may vary depending on the patient’s clinical condition. It is a minimally invasive procedure that is well tolerated, with a low risk of side effects, which are usually limited to mild, temporary local reactions.
It is important to emphasize that the management of Peyronie’s disease must be tailored to the individual and based on a thorough specialist evaluation. Hyaluronic acid injections are a valid option in the early stages or in selected cases, but they can be combined with other treatment strategies, such as oral medication, penile traction devices, or, in more advanced cases, surgical treatment.
An early, multidisciplinary approach not only improves clinical outcomes but also reduces the psychological impact of the condition, which is often met with embarrassment and reluctance. Promoting awareness and fostering open communication with healthcare professionals are therefore essential steps toward effective and informed management of the disease.
In a medical landscape increasingly focused on personalized care, hyaluronic acid injections represent an innovative and promising solution, capable of delivering tangible benefits through a conservative approach that respects the patient’s physiology.
